latest update:
[TrialBase DB]

trial summary · NCT07140315

DK222 Study at Hopkins

An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1

Trial record from the TrialBase DB dataset, status RECRUITING, condition Non-Small Cell Lung Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07140315phase PHASE1enrollment 6start 2027-01-31

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This Phase 1 clinical trial will test a new drug called \[18F\]DK222 in people with cancer. The goal is to see if the drug is safe, how it spreads through the body, how long it stays in the body, and how much radiation it gives off. \[18F\]DK222 is designed to attach strongly and specifically to a protein called PD-L1, which helps cancer hide from the immune system. This is a first in human study to collect preliminary safety and toxicity data of \[18F\]DK222.

Source record: https://clinicaltrials.gov/study/NCT07140315

Facts

registry idNCT07140315
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionNon-Small Cell Lung Cancer
sponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
sponsor classOTHER
enrollment6
start date2027-01-31
primary completion2028-01-31
completion2028-01-31
results postednot reported

Conditions

  • Non-Small Cell Lung Cancer
  • Urothelial Cancer

Interventions

  • [18F]DK222 radiotracer

Countries

  • United States

Intervention types: DRUG

Work with this record